Sangamo Therapeutics, Inc.
http://www.sangamo.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sangamo Therapeutics, Inc.
US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
US FDA Advisory Committee Conduct Could Take Center Stage in Lykos Appeal of MDMA Rejection
Sponsor of psychedelic PTSD treatment will try rarely successful formal dispute resolution process after receiving a complete response letter.
Lykos’s Knockback Could Be An Opportunity For Rivals
The group intends to appeal the US FDA’s rejection of its MDMA-based PTSD therapy, midomafetamine, but other psychedelics could advance in the meantime.
Financial Respite For Sangamo As Roche Signs Neurodegeneration Disease Pact
Deal Snapshot: The Swiss major has given Sangamo a cashflow injection in a deal to access two novel technologies to develop treatments for neurodegenerative diseases, including against tau for Alzheimer's.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Ceregene, Inc
- Sangamo Biosciences, Inc.
- TxCell S.A.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice